these patients is 3.6 years. Figure 2 shows OS curves of NPMm/ allografted (n ¼ 7), NPMm/non-allografted (n ¼ 27), NPMwt/ allografted (n ¼ 25) and NPMwt/non-allografted (n ¼ 16) patients. NPM status had a prognostic effect only in nonallografted patients (median not reached for NPMm, 24.4 months for NPMwt; P ¼ 0.04). Indeed, the NPMwt/non-allografted patients had a very poor 3 years OS compared to the other patients (P ¼ 0.02). By contrast, NPMm/non-allografted patients showed a 3-year OS probability of 75%.
Bortezomib (also known as PS-341; VELCADE) is a reversible proteasome inhibitor that selectively blocks the chymotryptic activity of the 26S proteasome. 1 Although the exact mechanism of action of bortezomib remains unclear, proteasome inhibitors are known to increase the activity and accumulation of proapoptotic, and suppress antiapoptotic molecules. Bortezomib has been identified as an attractive candidate for tumor therapy because it may overcome drug resistance in many malignancies.
Chronic lymphocytic leukemia (CLL) is an incurable disease. Novel, effective therapeutic agents are urgently required.
Bortezomib may have therapeutic potential in CLL.
1,2 However, despite significant apoptotic activity of bortezomib in CLL cells in vitro at nanomolar levels, including those with resistance to fludarabine, 1,2 there have been no reports of comparable activity in vivo. Preliminary results on a small number of patients with relapsed or resistant CLL were disappointing. 3, 4 Given the sensitivity of CLL to bortezomib in vitro, the lack of significant activity in vivo was unanticipated. We have confirmed that bortezomib is highly potent at inducing apoptosis at nanomolar concentrations in all CLL patient samples, irrespective of IGHV mutation status or fludarabine resistance (Table 1) . Furthermore, we show that uptake of bortezomib by red blood cells (RBCs) may be a significant contributory factor in the observed lack of activity in CLL patients in vivo. Different dosing schedules may be required to address this problem.
Freshly isolated mononuclear cells were purified from peripheral blood from 10 patients with CLL and incubated with bortezomib (0.1 nM-10 mM) for 1-24 h (data not shown). Cells from all patients studied underwent apoptosis as measured by Annexin V binding and uptake of propidium iodide (PI). Bortezomib induced a concentration-dependent induction of apoptosis, reaching a plateau at 10 nM. At concentrations of 10 nM and above, apoptosis was induced between 16 and 24 h. In CLL cells incubated with 10 nM of bortezomib for 24 h, the mean average percentage apoptosis (7s.e.m.) was 8573% compared with a background spontaneous apoptosis (vehicle only) of 3176%. Induction of apoptosis occurred irrespective of IGHV mutational status or clinical resistance to fludarabine (Table 1) . Apoptosis induction was confirmed by caspase activation, and activation of Bax (data not shown).
Mononuclear cells purified from an additional 36 patients were exposed to bortezomib (1, 10 or 100 nM), or MG132 (1 mM) for 6 and 24 h (Figure 1a and b) . Apoptosis was induced in all Figure 1a . We define X98% homology of the IGVH gene to its germline sequence as unmutated. % PS + cells denotes the % phosphatidyl serine externalization in peripheral blood mononuclear cells isolated from each patient after incubation with 100 nM bortezomib for 16 or 24 h.
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samples by 24 h treatment with either bortezomib (10 and 100 nM) or MG132 (Figure 1a) . Maximum levels of apoptosis were induced with 10 and 100 nM bortezomib by 16-24 h. Bortezomib at 1 nM did not induce significant apoptosis above control levels by 24 h. Figure 1b shows a representative time and concentration-dependent induction of apoptosis by bortezomib from one patient.
As bortezomib was potent at inducing apoptosis at low concentrations against CLL in vitro, it was surprising that the drug had not shown more clinical activity in this disease. We therefore used a whole-blood assay to mimic the in vivo environment more closely, comparing the activity of bortezomib in whole blood against purified mononuclear CLL cells in 13 patients (Figure 1c) . In whole-blood assays, the activity of bortezomib against CLL was blocked almost completely. In addition, we treated purified mononuclear cells from CLL patients with bortezomib in the presence or absence of autologous plasma; no significant loss of activity was observed under these conditions, suggesting that binding to plasma proteins did not play a significant role in this process (Figure 1d) .
We examined the possibility that bortezomib was being taken up by RBCs. It was hypothesized that uptake of bortezomib by RBCs rendered the drug unavailable for the induction of apoptosis in lymphocytes. Purified lymphocytes from five patients with CLL were incubated for 24 h in the presence of freshly separated autologous RBCs. There was a concentrationdependent protective effect of RBCs against bortezomibinduced apoptosis (Figure 2a) . Ten nanomolar bortezomib induced high levels of apoptosis, which were inhibited by the presence of RBCs from 5% upwards in a concentrationdependent trend. By 20% RBCs mixture, the levels of apoptosis were comparable with both the spontaneous background as well as levels observed in whole blood from the same patient. At 100 nM bortezomib, only 50% RBCs were able to abrogate apoptosis, although levels were still above background spontaneous apoptosis. In order to ensure that the presence of RBCs did not interfere with Annexin binding, samples were also tested for the loss of mitochondrial membrane potential using tetramethylethylester (TMRE) with comparable results (data not shown).
The distribution of bortezomib in the RBC fraction was also established in vivo in Cynomolgus monkeys. Figure 2b shows mean bortezomib concentrations in unfractionated blood, plasma and RBC following a 0.1 mg/kg intravenous (i.v.) administration on days 1, 4, 8 and 11. Plasma bortezomib concentrations decreased rapidly during the first 2 h and more rapidly than concentrations in the lymphocytes and RBCs following each bolus dose. In the RBC fraction and whole blood, the maximum bortezomib concentration was similar to the levels observed in plasma. However, 2 h after dosing, the bortezomib concentrations in the RBCs remained approximately twofold higher than concentrations observed in whole blood. These data illustrate that bortezomib in blood is selectively distributed to RBCs. Whilest 10 nM bortezomib is maintainable for several days in the in vivo model, it is likely that most of the drug administered for the first time is trapped within the RBCs component and not available to the target cells, as levels in the plasma compartment decrease rapidly within several hours. Bortezomib is currently in multiple clinical trials. As a single agent, it has been shown to be effective in multiple myeloma refractory to conventional chemotherapy, 5 and in addition has shown activity in patients with non-Hodgkin's lymphoma and specifically in mantle cell lymphoma. 3, 6 However, trials in CLL indicate that the drug may not be as effective in this patient population as would be anticipated from the in vitro data. Reasons for this lack of efficacy were previously not clear. We have developed a whole-blood apoptosis assay designed to mimic in vivo conditions more closely. Bortezomib-induced apoptosis in whole blood was markedly less than in isolated lymphocytes at comparable time points and concentrations. From these in vitro data, it was apparent that RBCs preferentially take up bortezomib, making the drug unavailable for biological activity. Similarly, the pharmacokinetic data in Cynomolgus monkeys were consistent with the preferential distribution of bortezomib to the RBC fraction, from which it was slowly redistributed to plasma. Our data suggest that besides other unknown factors, RBC uptake may be a contributing factor to the apparent lack of activity of bortezomib observed in vivo. The efficacy of flavopiridol in CLL has been shown to be impaired through its binding to albumin. 7 Use of infusional rather than bolus doses of the drug allowed increased efficacy. RBC uptake of bortezomib may similarly limit efficacy. In the case of CLL, bolus doses of bortezomib may fail to maintain serum levels of drug necessary to induce apoptosis in the whole blood. This may account for the lack of efficacy of bortezomib against cells in the peripheral blood. Whether infusional bortezomib rather than bolus would modulate bortezomib distribution to RBC and have increased antitumor efficacy remains to be determined. 
